Literature DB >> 26132471

Transcription factors that interact with p53 and Mdm2.

Kazushi Inoue1, Elizabeth A Fry1, Donna P Frazier1.   

Abstract

The tumor suppressor p53 is activated upon cellular stresses such as DNA damage, oncogene activation, hypoxia, which transactivates sets of genes that induce DNA repair, cell cycle arrest, apoptosis, or autophagy, playing crucial roles in the prevention of tumor formation. The central regulator of the p53 pathway is Mdm2 which inhibits transcriptional activity, nuclear localization and protein stability. More than 30 cellular p53-binding proteins have been isolated and characterized including Mdm2, Mdm4, p300, BRCA1/2, ATM, ABL and 53BP-1/2. Most of them are nuclear proteins; however, not much is known about p53-binding transcription factors. In this review, we focus on transcription factors that directly interact with p53/Mdm2 through direct binding including Dmp1, E2F1, YB-1 and YY1. Dmp1 and YB-1 bind only to p53 while E2F1 and YY1 bind to both p53 and Mdm2. Dmp1 has been shown to bind to p53 and block all the known functions for Mdm2 on p53 inhibition, providing a secondary mechanism for tumor suppression in Arf-null cells. Although E2F1-p53 binding provides a checkpoint mechanism to silence hyperactive E2F1, YB-1 or YY1 interaction with p53 subverts the activity of p53, contributing to cell cycle progression and tumorigenesis. Thus, the modes and consequences for each protein-protein interaction vary from the viewpoint of tumor development and suppression.
© 2015 UICC.

Entities:  

Keywords:  Arf; Dmp1 (Dmtf1); E2F1; Mdm2; YB-1; YY1; apoptosis; cancer; p53; polycomb; transcription factor

Mesh:

Substances:

Year:  2015        PMID: 26132471      PMCID: PMC4698088          DOI: 10.1002/ijc.29663

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  85 in total

1.  YB-1 as a cell cycle-regulated transcription factor facilitating cyclin A and cyclin B1 gene expression.

Authors:  Karsten Jurchott; Stephan Bergmann; Ulrike Stein; Wolfgang Walther; Martin Janz; Isabella Manni; Giulia Piaggio; Ellen Fietze; Manfred Dietel; Hans-Dieter Royer
Journal:  J Biol Chem       Date:  2003-04-14       Impact factor: 5.157

Review 2.  Long noncoding RNA, polycomb, and the ghosts haunting INK4b-ARF-INK4a expression.

Authors:  Francesca Aguilo; Ming-Ming Zhou; Martin J Walsh
Journal:  Cancer Res       Date:  2011-08-09       Impact factor: 12.701

3.  Yin Yang 1 plays an essential role in breast cancer and negatively regulates p27.

Authors:  Meimei Wan; Weiwei Huang; Timothy E Kute; Lance D Miller; Qiang Zhang; Heather Hatcher; Jingxuan Wang; Daniel B Stovall; Gregory B Russell; Paul D Cao; Zhiyong Deng; Wei Wang; Qingyuan Zhang; Ming Lei; Suzy V Torti; Steven A Akman; Guangchao Sui
Journal:  Am J Pathol       Date:  2012-03-20       Impact factor: 4.307

Review 4.  The oncogenic role of Yin Yang 1.

Authors:  Qiang Zhang; Daniel B Stovall; Kazushi Inoue; Guangchao Sui
Journal:  Crit Rev Oncog       Date:  2011

Review 5.  The ARF tumor suppressor: structure, functions and status in cancer.

Authors:  Peggy Ozenne; Beatrice Eymin; Elisabeth Brambilla; Sylvie Gazzeri
Journal:  Int J Cancer       Date:  2010-11-15       Impact factor: 7.396

6.  Critical roles of DMP1 in human epidermal growth factor receptor 2/neu-Arf-p53 signaling and breast cancer development.

Authors:  Pankaj Taneja; Dejan Maglic; Fumitake Kai; Takayuki Sugiyama; Robert D Kendig; Donna P Frazier; Mark C Willingham; Kazushi Inoue
Journal:  Cancer Res       Date:  2010-11-09       Impact factor: 12.701

Review 7.  The expanding universe of p53 targets.

Authors:  Daniel Menendez; Alberto Inga; Michael A Resnick
Journal:  Nat Rev Cancer       Date:  2009-10       Impact factor: 60.716

Review 8.  When mutants gain new powers: news from the mutant p53 field.

Authors:  Ran Brosh; Varda Rotter
Journal:  Nat Rev Cancer       Date:  2009-08-20       Impact factor: 60.716

Review 9.  Modes of p53 regulation.

Authors:  Jan-Philipp Kruse; Wei Gu
Journal:  Cell       Date:  2009-05-15       Impact factor: 41.582

10.  Dmp1 physically interacts with p53 and positively regulates p53's stability, nuclear localization, and function.

Authors:  Donna P Frazier; Robert D Kendig; Fumitake Kai; Dejan Maglic; Takayuki Sugiyama; Rachel L Morgan; Elizabeth A Fry; Sarah J Lagedrost; Guangchao Sui; Kazushi Inoue
Journal:  Cancer Res       Date:  2012-02-13       Impact factor: 12.701

View more
  35 in total

1.  Tumor suppression by the EGR1, DMP1, ARF, p53, and PTEN Network.

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Cancer Invest       Date:  2018-11-05       Impact factor: 2.176

Review 2.  p53 and RAD9, the DNA Damage Response, and Regulation of Transcription Networks.

Authors:  Howard B Lieberman; Sunil K Panigrahi; Kevin M Hopkins; Li Wang; Constantinos G Broustas
Journal:  Radiat Res       Date:  2017-01-31       Impact factor: 2.841

3.  Aberrant expression of p16INK4a in human cancers - a new biomarker?

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Cancer Rep Rev       Date:  2018-01-15

4.  Aberrant Expression of p14ARF in Human Cancers: A New Biomarker?

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Tumor Microenviron       Date:  2019-02-04

5.  Aberrant expression of cyclin D1 in cancer.

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Sign Transduct Insights       Date:  2015-09-20

6.  N6-methyladenosine mediates arsenite-induced human keratinocyte transformation by suppressing p53 activation.

Authors:  Tianhe Zhao; Donglei Sun; Manyu Zhao; Yanhao Lai; Yuan Liu; Zunzhen Zhang
Journal:  Environ Pollut       Date:  2020-01-07       Impact factor: 8.071

Review 7.  Oncogenic and tumor-suppressive mouse models for breast cancer engaging HER2/neu.

Authors:  Elizabeth A Fry; Pankaj Taneja; Kazushi Inoue
Journal:  Int J Cancer       Date:  2016-09-12       Impact factor: 7.396

8.  Aberrant expression of ETS1 and ETS2 proteins in cancer.

Authors:  Elizabeth A Fry; Kazushi Inoue
Journal:  Cancer Rep Rev       Date:  2018-04-23

9.  Haploinsufficient tumor suppressor genes.

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Adv Med Biol       Date:  2017 1st Quarter

Review 10.  Novel Therapies in Myelofibrosis: Beyond JAK Inhibitors.

Authors:  Julian A Waksal; John Mascarenhas
Journal:  Curr Hematol Malig Rep       Date:  2022-08-19       Impact factor: 4.213

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.